Journals / Cerrahpaşa Tıp Dergisi / 2007 / Cilt: 38 - Sayı: 2

The place of endobronchial interventional procedures and intratumoral chemotherapy in the therapeutic strategy of lung cancer

Endobronşiyal girişimsel yöntemler ve intratümöral kemoterapinin akciğer kanserinin tedavi stratejisindeki yeri

Pages
69–80
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The potential synergistic efficiency of EITC when combined with standard lung cancer therapies, brachytherapy and with photodynamic therapy was discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The clinical studies in the last decades have demonstrated that the obstruction in the proximal airways due to non-smallcell- lung-cancer influences a negative effect on the outcome of disease.
📊
Key Findings & Data:Moreover the clinical studies have demonstrated that the alleviation of the obstruction in the airways by the available interventional bronchoscope procedures ameliorates the efficiency of the standard therapeutic modalities of lung cancer as well as the survival rates of patients.
💡
Conclusion & Impact:The potential synergistic efficiency of EITC when combined with standard lung cancer therapies, brachytherapy and with photodynamic therapy was discussed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The clinical studies in the last decades have demonstrated that the obstruction in the proximal airways due to non-smallcell- lung-cancer influences a negative effect on the outcome of disease. Moreover the clinical studies have demonstrated that the alleviation of the obstruction in the airways by the available interventional bronchoscope procedures ameliorates the efficiency of the standard therapeutic modalities of lung cancer as well as the survival rates of patients. In this present paper the advantages and disadvantages of different interventional endobronchial therapeutic modalities in the treatment of endobronchial malignancies were reviewed. Especially the effectiveness of using different methods sequentially or concomitantly in the same patient is emphasized. The interventional endoscopic procedures were studied in two main groups: 1- Ablative destructive methods with non-specific effects on the tissue: a) thermic procedures, such as electrocautery, laser photoresection, argon- plasma coagulation, cryotherapy; b) mechanical procedures, such as piecemeal resection with forceps, dilatation with balloon catheter, installation a stent. 2- Procedures with specific effects, destroying exclusively the cancerous cells: brachytherapy, photodynamic therapy. In addition to these, the novel paradigm of endobronchial intratumoral chemotherapy was described as interventional therapeutic modalities with specific effect on malignant cells alike brachytherapy and photodynamic therapy. The potential synergistic efficiency of EITC when combined with standard lung cancer therapies, brachytherapy and with photodynamic therapy was discussed.

Özet

Son yıllarda yapılan klinik araştırmalar “küçük hücreli dışı akciğer kanserinde” proksimal hava yollarında tümör yerleşimine bağlı obstrüksiyonun hastanın prognozunu olumsuz yönde etkilediğini, buna karşılık havayolu obstrüksiyonunun girişimsel bronkoskopi yöntemleri ile ortadan kaldırılmasının standart kanser tedavilerinin daha başarılı olmasını ve hastaların yaşam süresinin uzamasını sağladığını göstermiştir. Bu derleme yazısında girişimsel endobronşiyal tedavi yöntemleri aşağıdaki gibi iki ana guruba ayrılarak incelenmiştir: 1- non-spesifik yöntemler: a) termik yöntemler: elektro koter, lazer foto rezeksiyonu, argon plazma koagülasyonu ve krioterapi; b) mekanik yöntemler: forseps rezeksiyonu, balon kateter ile dilatasyon ve stent uygulaması. 2- kanser hücrelerini (normal hücreleri zedelemeden) spesifik olarak etkileyen yöntemler: brakiterapi, fotodinamik tedavi, endobronşiyal intratümöral kemoterapi. Yazıda yeni bir paradigma olan “endobronşiyal intratümöral kemoterapinin” tanımlaması yapılarak endikasyonları ve bronkoskopik girişimsel yöntemler arasındaki yeri belirlenmiştir. Endobronşiyal intratümöral kemoterapinin etki prensibinin fotodinamik tedavi ve brakiterapide olduğu gibi kanserli hücreleri normal hücrelere zarar vermeksizin nekrozlaştırdığı için spesifik olduğu vurgulanmıştır. Buna ek olarak, endobronşiyal intratümöral kemoterapinin loko-rejyonal neoadjuvant bir kemoterapi olarak radyoterapi, intravenöz kemoterapi ve diğer endobronşiyal girişimsel yöntemler ile eş zamanlı veya birbiri ardına kullanılmasının potansiyel yararları gözden geçirilmiştir

🔖

Cite This Article

PAPİLA, Ç., PAPİLA, İ., ÇELİKOĞLU, F., ÇELİKOĞLU, İ. (2022). The place of endobronchial interventional procedures and intratumoral chemotherapy in the therapeutic strategy of lung cancer. Cerrahpaşa Tıp Dergisi, Cilt: 38 - Sayı: 2, 69–80. https://ajindex.com/articles/473341

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543
  2. Minna JD, Higgins GA, Glastein E. Cancer of the lung. In: Devita VT, Hellman S, Rosenberg SA (eds). Principles and practice of oncology, 2nd edn.Lppincott, Philadelphia, 1985; 518-526
  3. Jemal A, Murray T,Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics. 2005. Ca Cancer J Clin 2005; 55: 10-30
  4. World health organization: Histological typing of lung cancer and pleural tumors. Berlin, Springer 1999
  5. Cersosomo RJ. Lung cancer: a review. Am J Health Syst Pharm 2002; 59: 611- 642
  6. Matthews M.J. Problems in morphology and behavior of bronchopulmonary malignant disease. Israel L, Chahinian A.P. eds. Lung cancer: Natural History, prognosis and therapy. Academic press New York 1976: 23-62
  7. Group L.L.C.S. Patterns of failure in patients with resected stage I and II non-small-cell carcinoma of the lung. Ann Surg 1987; 205: 67-71
  8. Kotlyarov EV, Rukosuyev AA. Long-term results and patterns of disease recurrence after radical operations for lung cancer. J Thorac Cardiovasc Surg 1991; 102: 24-28 [Abstract]
  9. Wingo PA, Tong T,Bolden S, Cancer statistics 1995. Cancer J Clin 1995; 45: 8-30
  10. Nesbitt JC, Putnam JB, Walsh GL, et al. Survival in early stage non-small cell lung cancer. Ann Thorac Surg 1995; 60: 466-472
  11. Spiro SG, Porter JC. Lung Cancer—Where Are We Today? Current Advances in Staging and Nonsurgical Treatment. Am J Resp Critcl Care Med 2002; 166: 1166-1196
  12. Gatzemeir U, Von Pawel L, Gottfried M, et al. Phase III comparative study of high dose Cisplatin versus a combination of paclitaxel and Cisplatin in patients with advanced non-small lung cancer. Proc Am Soc Clin Oncol 1998; 17: 454a
  13. Ning S, Yu N, Brown D.M., Kanekal S, Knox SJ. Radiosensitization by intratumoral administration of cisplatin in a sustained-release drug delivery system. Radiother Oncol 1999; 50: 215-223
  14. Trovo MG, Minatel E, Veronesie A, Roncadin M, De Paoli A, Franchin G, et al. Combined radiotherapy and chemotherapy vs. radiotherapy alone in locally advanced bronchogenic carcinoma: a randomized study. Cancer 1990; 65: 400-404
  15. Trovo MG, Minatel E, Franchin G, Boccieri MG, Nascimben O, Bolzicco G, et al. Radiotherapy (RT) versus RT enhanced by cisplatin (CDPG) in stage III non small-cell lung cancer (NSCLC): randomized cooperative study. Lung Cancer 1991; 7: 158
  16. Shaake –Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J. Effects o